TechVoice: Can Stemcell Therapy Be The Answer To Minimising Fatalities Caused By COVID19?

Terms of use

Terms of Use

The use of this site and the content contained therein is governed by the Terms of Use. When you use this site you acknowledge that you have read the Terms of Use and that you accept and will be bound by the terms hereof and such terms as may be modified from time to time.

All text, graphics, audio, design and other works on the site are the copyrighted works of nasscom unless otherwise indicated. All rights reserved.
Content on the site is for personal use only and may be downloaded provided the material is kept intact and there is no violation of the copyrights, trademarks, and other proprietary rights. Any alteration of the material or use of the material contained in the site for any other purpose is a violation of the copyright of nasscom and / or its affiliates or associates or of its third-party information providers. This material cannot be copied, reproduced, republished, uploaded, posted, transmitted or distributed in any way for non-personal use without obtaining the prior permission from nasscom.
The nasscom Members login is for the reference of only registered nasscom Member Companies.
nasscom reserves the right to modify the terms of use of any service without any liability. nasscom reserves the right to take all measures necessary to prevent access to any service or termination of service if the terms of use are not complied with or are contravened or there is any violation of copyright, trademark or other proprietary right.
From time to time nasscom may supplement these terms of use with additional terms pertaining to specific content (additional terms). Such additional terms are hereby incorporated by reference into these Terms of Use.

Disclaimer

The Company information provided on the nasscom web site is as per data collected by companies. nasscom is not liable on the authenticity of such data.
nasscom has exercised due diligence in checking the correctness and authenticity of the information contained in the site, but nasscom or any of its affiliates or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this site. The information from or through this site is provided "as is" and all warranties express or implied of any kind, regarding any matter pertaining to any service or channel, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement are disclaimed. nasscom and its affiliates and associates shall not be liable, at any time, for any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communications line failure, theft or destruction or unauthorised access to, alteration of, or use of information contained on the site. No representations, warranties or guarantees whatsoever are made as to the accuracy, adequacy, reliability, completeness, suitability or applicability of the information to a particular situation.
nasscom or its affiliates or associates or its employees do not provide any judgments or warranty in respect of the authenticity or correctness of the content of other services or sites to which links are provided. A link to another service or site is not an endorsement of any products or services on such site or the site.
The content provided is for information purposes alone and does not substitute for specific advice whether investment, legal, taxation or otherwise. nasscom disclaims all liability for damages caused by use of content on the site.
All responsibility and liability for any damages caused by downloading of any data is disclaimed.
nasscom reserves the right to modify, suspend / cancel, or discontinue any or all sections, or service at any time without notice.

For any grievances under the Information Technology Act 2000, please get in touch with Grievance Officer, Mr. Anirban Mandal at data-query@nasscom.in.

New

See all

No notification found.

TechVoice: Can Stemcell Therapy Be The Answer To Minimising Fatalities Caused By COVID19?

Sindhuja Balaji

@sindhuja.balaji

April 23, 2020

Leader Talk COVID-19

3288

Vipul Jain, CEO, Advancells

The world is passing through quite a rough phase. The global economy is crashing, healthcare systems worldover are under immense strain, the price of crude oil has fallen below zero for the first time, companies are slashing jobs and scaling back operations, people are holed up at home working remotely, countries are in lockdown; fully aware of the economic slide this is causing. All this because of a virus. So what is happening around the world? Do you really need to take a deep dive into the data and the calculus generated so far? Do you really have the time to analyze the same and take action accordingly?

Experts are suggesting, if you really start doing that, other nations will soon slip into the nightmare currently is being faced by USA, Italy, Spain, China – all of which are grappling with a high mortality rate caused by COVID19. Contrary to which, if you start working on it quickly, you can still pass through the crisis.

Since COVID-19 has been declared to be pandemic by the World Health Organization; each country is facing a rapid spike in a number of infected people. Remember, in this, we are ignoring cases, which have still not been tested; once tested there can be havoc in a number of confirmed cases, which may have infected more people around. This can be explained in a more simplified language as one infected person can contaminate 100 other people, who are in close contact; and is sufficient to raise the curve rapidly. One of the primary questions that need immediate attention here is whether your country is adequately equipped with necessary after cares? If not then the only probable solution is to bend the curve; by increasing the immunity, being healthier and pushing the chance of being infected into the future.

Countries like Japan, Germany, and South Korea have bent the curve to an extent, where they have been able to offer the right care to infected patients and have provided sufficient precautionary options to help people to strengthen their immunity, lower inflammation, minimize spread.

So this is exactly what I mean by bending the curve, leading to spread out cases over a longer period of time; by being stronger in you.

How about “Bending the curve” with the help of stem cell therapy?

It is indeed a hard truth of our healthcare system that we need to believe and understand our system has limitations. Reports from Italy are suggesting that numbers of deaths are more not because they couldn’t be saved in the viral pandemic; but because they could not get sufficient aftercare that they needed the most.

And the only option would be to delay the chances of being infected, and stem cells can definitely help you in doing so!

Recently, China has published a case study wherein a 65-year-old lady, critically suffering from COVID-19 was offered Mesenchymal stem cells isolated from the Umbilical Cord. The study concluded with significant clinical outcomes, higher tolerance, and reduced respiratory inflammation post stem cell therapy.

In another location of Wuhan, which has been noted to be an epicenter of the corona outbreak, 7 patients suffering from infection were administered with Mesenchymal stem cells isolated from Umbilical Cord and have been reported to have a complete recovery from the infection. Further studies in the same, have cleared proved that patients who had undergone stem cell therapy post-infection were reportedly had decreased pool of inflammatory cytokines that have been reportedly the primary cause of deaths in COVID-19 infections.

Mesenchymal Stem cells isolated from Umbilical Cord Wharton’s jelly are being reported as the only possible solution at this moment to minimize the inflammatory cytokine pools in the circulation and prevent death associated with the infection. The only challenge that can be faced is travel associated with stem cell therapy, and we have a possible solution over the issue; but the question is, are you with us in bending the curve?

Vipul Jain is the CEO of Advancells. This piece has been published as part of our series #TechVoice. To contribute, write to sindhuja@nasscom.in

Liang B, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. https://3n30av2dln0g4fmlc03hpv0p-wpengine.netdna-ssl.com/wp-content/uploads/2020/03/202002.00084v1.pdf.pdf. Accessed 3/15/20.

(2) Leng Z et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging and Disease. 2020 , 0 (0): 216-228 https://doi.org/10.14336/AD.2020.0228

COVID19 stemcell therapy Advancells Vipul Jain mortality rate COVID19

Disclaimer

That the contents of third-party articles/blogs published here on the website, and the interpretation of all information in the article/blogs such as data, maps, numbers, opinions etc. displayed in the article/blogs and views or the opinions expressed within the content are solely of the author's; and do not reflect the opinions and beliefs of NASSCOM or its affiliates in any manner. NASSCOM does not take any liability w.r.t. content in any manner and will not be liable in any manner whatsoever for any kind of liability arising out of any act, error or omission. The contents of third-party article/blogs published, are provided solely as convenience; and the presence of these articles/blogs should not, under any circumstances, be considered as an endorsement of the contents by NASSCOM in any manner; and if you chose to access these articles/blogs , you do so at your own risk.